Definium Therapeutics (DFTX) Gains from Investment Securities (2023 - 2026)

Definium Therapeutics (DFTX) has reported Gains from Investment Securities for 4 consecutive years, with $20.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 386.41% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $49.9 million (up 308.24% YoY), while the FY2025 annual figure was $22.8 million, up 43.22% from the prior year.
• Gains from Investment Securities climbed to $20.0 million in Q1 2026 per DFTX's latest filing, from $5.1 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $32.9 million in Q1 2024 and bottomed at -$13.4 million in Q2 2024.
• Historically, Gains from Investment Securities has averaged $5.0 million across 4 years, with a median of $3.0 million in 2023.
• On a YoY basis, Gains from Investment Securities climbed as much as 534.39% in 2024 and fell as far as 993.95% in 2024.
• Definium Therapeutics' Gains from Investment Securities stood at $3.0 million in 2023, then jumped by 63.68% to $4.9 million in 2024, then advanced by 4.2% to $5.1 million in 2025, then jumped by 296.4% to $20.0 million in 2026.
• Business Quant data shows DFTX's Gains from Investment Securities at $20.0 million in Q1 2026, $5.1 million in Q4 2025, and $22.5 million in Q3 2025.